Richard J. Prati, a seasoned business executive, investor, entrepreneur, philanthropist, and hands-on turnaround specialist, has served as Chief Executive Officer of Life Care Medical Devices since 2013 (www.lcmd.com), and CEO of Prati Management, a Family Office since 2012. Richard has 25 years of proven financial leadership and operational execution in investment banking, institutional equity sales, and professional investment management. As a Principal at several notable Wall Street investment firms, Mr. Prati has a strong history of exceptional value creation and a successful track record of transformational, business turnaround expertise including sourcing and executing transactions, accessing the public and private markets and catalyzing sizable revenue growth production. He has guided a wide range of emerging and established public and private entities in industries ranging from healthcare, biotech, medical devices, conglomerates, retail, industrials, information technology and semiconductors companies.
Mr. Prati Co-Founded, a young medical technology start-up, Singular Medical Technologies, Inc. (http://singmedtech.com/), and serves as Chairman. Singular addresses in a unique and innovative way the global problem of PACS incompatibility and hospital consolidation. Mr. Prati also recently served as Vice Chairman of PVG Asset Management (www.pvgassetmanagement.com), a fund family with nearly $1 Billion in assets for three years, and is a board member and early-stage investor of the privately-held Centennial Brands company. In 2002 Mr. Prati was one of two co-founders of American Technology Research (AmTech), an independent research broker/dealer and negotiated the $35 million sale of AmTech to Broadpoint in 2008. He then served as President and Vice Chairman of the equities division of Gleacher and Company (GLCH, which merged with Broadpoint AmTech shortly after the acquisition of AmTech). In 2010, Mr. Prati accepted the position Senior Managing Director of Equities at Sterne Agee, a large regional brokerage firm that was recently acquired by Stifel Nicolaus. Prior to founding AmTech, Mr. Prati was a Senior Partner at SoundView Technology Group, ran the west coast and launched the Denver office as well as establishing firm records as the top revenue producer his final three years. Richard served as an Executive Director at SG Warburg (UBS) in institutional equity sales, after embarking on his successful Wall Street career as an investment banker at Dean Witter Reynolds (acquired by Morgan Stanley). He earned his MBA from the William E. Simon Graduate School of Business Administration at the University of Rochester and his B.S in Economics from Vanderbilt University.
I usually write about airline, aerospace, transport and industrial stocks as I have followed these industries for many years, developed contacts and an in-depth understanding of their inner workings. I will post detailed analysis and a guide to most developments that occur at all stocks I regularly cover. Currently I cover most major U.S airlines, and aerospace firms. Over time I hope to expand my coverage of quality aerospace, airline, transport and industrial stocks.
One area I focus on is the airline industry. The airline industry is undergoing fundamental change, with only 4 major U.S airlines now, down from 12 just over 10 years ago. This consolidation has rationalized the industry and for the first time in history made it worthy of investing and making a profit in. All major U.S airlines with the exception of Southwest are still not investment grade and still have many hurdles ahead, leaving nice upside for investors willing to get into the industry at this stage.
In general, I love trading value stocks that I believe have significant upside compared to downside long term. I prefer medium cap companies with compelling value, growth, or momentum. I focus on a select list of quality stocks that I have rigorously vetted which I update weekly. I like to create high quality in depth articles on stocks that I am passionate about and hope they will be of help to other investors out there or those looking for ideas to get started.
Mr. Axler is the Founder and Chief Investment Officer of Spruce Point Capital Management, an activist hedge fund manager. Mr. Axler also co-founded Prescience Point Research Group (2012-2014). Mr. Axler specializes in activist short-selling, forensic financial research, and has exposed over $1.0 billion of alleged listed frauds on Nasdaq and the NYSE. Prior to founding his company in 2009, Mr. Axler spent eight years as an investment banker with Credit Suisse and Barclays Capital where he structured and executed billions of dollars of financing, derivative risk management, and M&A deals for leading Fortune 500 clients.
Mr. Axler is a contributing writer to Seeking Alpha, has been profiled in Barrons, and in the book "The Happiness Advantage: The Seven Principles of Positive Psychology That Fuel Success and Performance at Work." Mr. Axler's short research has been profiled by the National Bureau of Economic Research (NBER) in an analysis entitled "How Constraining Are Limits to Arbitrage? Evidence from a Recent Financial Innovation," and shown to produce superior investment returns. In addition, according to a research study from Sumzero analyzing 12,000 analysts recommendations since 2009, Mr. Axler ranked #1 globally for idea performance. A recent analysis by Sentieo ranked Mr. Axler's @sprucepointcap profile the 13th most influential financial blogger on Twitter.
Mr. Axler graduated from Yale University with a masters degree in Statistics, and received both a Bachelor of Arts degree in Statistics and a Bachelor of Science in Marketing and Business Administration from Rutgers College, where he graduated with Summa Cum Laude and Phi Beta Kappa honors.
Professional investor and overall good guy.
By reading Mako Research reports, you agree to use the information at your own risk. In no event should Mako Research or any affiliated party be liable for any direct or indirect trading losses caused by information contained in the research reports. Research reports are not investment advice or a recommendation or solicitation to transact any securities. Mako Research is not a registered investment advisor. You agree to do your own research and due diligence before making any investment decision with respect to securities covered herein. You should assume that Mako Research stands to profit in the event the issuer’s stock declines. Research reports may contain opinions, which are based upon generally available public information, field research, inferences and deductions through due diligence and analytical processes. All information is believed to be accurate and reliable, and has been obtained from public sources. Mako Research makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information. All expressions of opinion are subject to change without notice, and Mako Research is not obligated to update or supplement any reports or any of the information, analysis and opinion contained in them. You should assume that Mako Research has and/or will submit findings with the Securities Exchange Commission, and other entities that may find the information useful.
Mid Market M&A consultant specializing in technology and energy industries. Individual Investor for over 25 years. Growth oriented investments primarily in market leaders and technology leaders. Investment philosophy is long term buy and hold with average holding time of several years.
I have a keen sense of cutting through management and Investment banker commentary and seeing true value of companies. A lot of my views tend to be controversial for that reason but at the same time remarkably accurate.
To get a feel for my writing, readers can puruse a few of my recent against the grain calls:- with extremely high success rates.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Dane Capital Management is a private investment management company, open to institutions and accredited investors, that focuses on value and special situations investments.
Earned a Doctorate in Pharmacy (Pharm.D.) in 2010 and Pre-Pharmacy/B.S. in Molecular Biology in 2006. Over six years of direct experience in translational research in oncology investigating the molecular/cellular mechanisms of carcinogenesis focused on biomarker identification and validation working in a multi-disciplinary matrix environment across academia, contract research organizations and industry.
Analyst Tip Ranks: https://www.tipranks.com/experts/dr.-paul-nunzio-desantis%252C-pharm.d
I am currently a Junior at the George Washington University and have been investing since the sixth grade with my own money. I am very interested in the pharmaceutical sectors, but will buy just about any stock if I feel that the company is undervalued. I hope to provide some helpful insight, and to in turn learn a lot from the rest of the investment community.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our Editorial Team is comprised of individuals with a strong background in science, medicine and the business of successfully commercializing therapeutics, medical devices, diagnostics and healthcare services. Our ultimate objective is to leverage the knowledge, experience, and relationships of our contributors to introduce our subscribers to profitable long and short investment opportunities in the healthcare sector.
Successfully trading, and investing in emerging growth healthcare companies is a difficult task. Over 90% of drugs never make it out of the clinic. Huge capital requirements along the way result in highly dilutive equity financings often done on the backs of retail investors. At PropThink, we believe that due diligence is the key to success in this industry. We leverage a combined 50 years of experience in science, medicine, legal, regulatory affairs, finance, and operational industry experience to analyze companies at a highly technical level. This detailed analysis and due diligence process defines our editorial strategy and provides our subscribers a high level of confidence in our research. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued.
Visit PropThink.com to see all of our coverage and research, and subscribe to our free newsletter to receive reports, articles, and trading alerts.
Randy Burd, Ph.D. is the Director of Research at BerylStone and an Associate Professor at University of Arizona. Randy received his Ph.D. in Molecular and Cellular Biophysics in 1998 from the Roswell Park Cancer Institute in Buffalo, New York and has worked in the area of pharmaceutical and biotechnology research for over a decade. In 2002 he was appointed the director of Pre-Clinical Therapeutics at Thomas Jefferson University. In 2005 he was recruited to the University of Arizona. Randy joined BerylStone in 2011 and currently co-manages BerylStone Investment's Managed Portfolios.
Vice President level professional with over six years of experience at a bulge bracket investment bank supporting Securities Sales & Trading. I have an undergraduate degree in Finance and am currently pursuing my MBA with a concentration in Finance as well. I have ten plus years of investing experience utilizing stocks, bonds, ETF’s, mutual funds and options to manage personal and family accounts.
Although all of my professional experience is on the Securities sell-side, I hope to move into a full time asset management/investment analysis role upon graduation from my MBA program. I follow the markets as a whole, from macroeconomic events to equities across the entire market cap spectrum, but my Seeking Alpha research and publications tend to focus on the small and mid-cap space. I believe this is the area in which the most value can be added from an independent and/or buy-side analyst standpoint, given the typical lack of coverage of these companies by most of the larger institutions. I am looking to leverage the Seeking Alpha platform in order to both promote and improve my investment analysis and writing skills, and hope that it could potentially open doors for me.
If you have questions about my publications, would like to know more about me or would just like to bounce around ideas, feel free to message me via Seeking Alpha.
It is very hard or impossible to time the broad market consistently — there are no famous investors that got rich by consistently knowing what the broad market would do next. This only makes sense, as there are just too many variables in the broad market. But there are many famous investors who got rich analyzing individual securities, and this is where you should put your focus. You can get an edge in individual securities. Joe Springer was the number 1 ranked stock analyst in the world by tipranks.com. Joe is a Certified Technical Trainer, and enjoys teaching about the stock market as well as managing portfolios. If you would like to follow Joe on Twitter, his handle is @JoeSpringer.
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
Steve Zachritz, "Zman", is an investor/trader who specializes in the energy sector. He has managed small cap growth portfolios, been an energy banker, and a sell side exploration and production analyst (Prudential and Jefferies) in his 20 years in the financial markets. His daily writeups address developments in that sector and the potential impact on publicly traded stocks, options, and futures.
Visit his site: Zman's Energy Brain http://www.zmansenergybrain.com
Follow our tweets at ZmansEnrgyBrain
I am a scientist by training and trade. I have Bachelor's and Master's degrees in Math, and Doctorate in Computer Science. My passion is building mathematical models of stock behavior, and implementing them in computer simulations. But after years of investing with both technical and fundamental approaches, my biggest profits have consistently come from in-depth study of all aspects of a company.
Led by MIT engineers and Wall Street analysts, Trefis.com helps you understand how a company's products, that you touch, read, or hear about everyday, impact its stock price.
Surprisingly, the founders of Trefis discovered that along with most other people they just did not understand even the seemingly familiar companies around them: Apple, Google, Coca Cola, Walmart, GE, Ford, Gap, and others.
This might include you though you may have invested money in these companies, or may have been working with one of them for years as an employee, or have consulted with them as an expert for a long time.
Consider these questions:
•What % of Apple's stock price is iPhones? (Q: Is it 5%, 25%, or 50%?)
•What % of Dell's stock price is Dell Notebooks?
•If Bing took half the market share from Google Search, what % upside could there be for Microsoft’s stock?
On Trefis you will get answers to questions like above.
You can play with assumptions, or try scenarios, as-well-as ask questions to other users and experts. The platform uses extensive data to show in a single snapshot what drives the value of a company's business.
Trefis makes the same content, data, and tools that are currently available only to professional investors today, accessible to everyone. Importantly, it makes the extensive data/tools easy to use and understand, allowing investors to leverage the platform in their decision making much more efficiently than anything else available.
Trefis is currently used by hundreds of thousands of investors, company employees, and business professionals.
Starks has worked for well-known energy companies in marketing, planning, and engineering. She brings this experience, along with extensive research and investing, to profiling energy companies by investing segment in her monthly newsletter.
I've been in investment management since 1990, currently as the money manager for Worm Capital. I received my law degree from the University of Oregon in 1984, worked as an accountant for the international accounting firm KPMG, then got involved in investing. I've written over 300 columns for The Financial Times, TheStreet.com, Realmoney.com and SeekingAlpha.com.